References of "HUSTINX, Roland"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailFDG-PET imaging for diagnosing bone infection.
LETESSON, G.; FOIDART-WILLEMS, Jacqueline ULg; HUSTINX, Roland ULg

in Journal of Nuclear Medicine (The) (2005), 46(SUPPL), 323

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailIntratissular lymphaticovenous anastomoses demonstrated by preoperative injection of 99mTc colloids.
HEYMANS; FALLAIS, C.; HUSTINX, Roland ULg

in Journal of Nuclear Medicine (The) (2005), 46(SUPPL), 326

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of therapy for lymphoma.
Jerusalem, Guy ULg; Hustinx, Roland ULg; Beguin, Yves ULg et al

in Seminars in Nuclear Medicine (2005), 35(3), 186-96

Positron emission tomography (PET) using (18)F-fluorodeoxyglucose ((18)F-FDG) is the best noninvasive imaging technique for to assess response in patients suffering from lymphoma. Early response ... [more ▼]

Positron emission tomography (PET) using (18)F-fluorodeoxyglucose ((18)F-FDG) is the best noninvasive imaging technique for to assess response in patients suffering from lymphoma. Early response evaluation ("interim PET") after one, a few cycles, or at midtreatment can predict response, progression-free survival, and overall survival. We calculated from data of 7 studies an overall sensitivity to predict treatment failure of 79%, a specificity of 92%, a positive predictive value (PPV) of 90%, a negative predictive value (NPV) of 81%, and an accuracy of 85%. Although it is not yet indicated to change patient management based on residual (18)F-FDG uptake on interim scan in chemotherapy-sensitive patients, prospective studies evaluating the role of an interim PET in patient management clearly are warranted. (18)F-FDG PET also has an important prognostic role in relapsing patients after reinduction chemotherapy before high-dose chemotherapy (HCT) followed by autologous stem cell transplantation (ASCT). However, all chemotherapy-sensitive patients remain candidates for HCT followed by ASCT, even if (18)F-FDG PET showed residual (18)F-FDG uptake. We calculated from data of 3 studies an overestimated risk of relapse in 16% of all PET-positive patients. Some patients with residual (18)F-FDG uptake will have a good outcome after HCT followed by ASCT. (18)F-FDG PET is the imaging technique of choice for end-of-treatment evaluation. However, (18)F-FDG is not specific for tumoral tissue. Active inflammatory lesions and infectious processes can be falsely interpreted as malignant residual cells. However, a negative (18)F-FDG PET cannot exclude minimal residual disease. Consequently, it is always indicated to correlate PET findings with clinical data, other imaging modalities, and/or a biopsy. We calculated, from data of 17 studies in end-of-treatment evaluation, a sensitivity of 76%, a specificity of 94%, a PPV of 82%, a NPV 92%, and an accuracy of 89%. [less ▲]

Detailed reference viewed: 39 (6 ULg)
Full Text
Peer Reviewed
See detailPositron emission tomography imaging for lymphoma.
Jerusalem, Guy ULg; Hustinx, Roland ULg; Beguin, Yves ULg et al

in Current Opinion in Oncology (2005), 17(5), 441-5

PURPOSE OF REVIEW: To review the current role and the limitations of F-fluorodeoxygenase positron emission tomography in the management of lymphoma, with a particular focus on studies published since ... [more ▼]

PURPOSE OF REVIEW: To review the current role and the limitations of F-fluorodeoxygenase positron emission tomography in the management of lymphoma, with a particular focus on studies published since January 2004. RECENT FINDINGS: F-fluorodeoxygenase positron emission tomography should be routinely performed at the initial diagnosis of patients with suffering from Hodgkin's disease because it adds useful informations to conventional staging techniques. Residual F-fluorodeoxygenase uptake is an important prognostic factor after one or a few cycles of chemotherapy, but it is clearly too early to change patient treatment on the basis of F-fluorodeoxygenase positron emission tomography results. F-fluorodeoxygenase positron emission tomography is the best noninvasive imaging technique after treatment; however, it is always indicated to correlate positron emission tomography findings with clinical data, other imaging modalities, a biopsy, or all three to reduce the risk of false positive results. There are some concerns about the positive predictive value of positron emission tomography after treatment, especially in childhood lymphoma. Clinicians should be aware of positron emission tomography findings in specific clinical conditions in this patient population. F-fluorodeoxygenase positron emission tomography combined with computed tomography offers advantages over the two used separately and read side by side. It may be particularly useful for the planning of radiation therapy or for the planning of a surgical biopsy. Several studies have shown that F-fluorodeoxygenase positron emission tomography is definitively superior to Ga scintigraphy. New radiotracers such as F-fluorothymidine may be useful for the noninvasive assessment of proliferation in vivo. SUMMARY: F-fluorodeoxygenase positron emission tomography has become the most important nuclear medicine imaging modality in the field of lymphoma. It should be routinely used in the treatment of lymphoma patients. [less ▲]

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailL'image du mois. Mise en evidence d'une metastase intracanalaire rachidienne d'un carcinome pulmonaire par TEP/TDM
Ancion, Geoffrey; Foidart-Willems, J.; Willems, V. et al

in Revue Médicale de Liège (2005), 60(7-8, Jul-Aug), 637-8

Detailed reference viewed: 61 (2 ULg)
Full Text
See detailWhole-Body Positron Emission Tomography using 18F-Fluorodeoxyglucose for Staging Response Assessment in Hodgkin's Disease
Jerusalem, Guy ULg; Hustinx, Roland ULg; Beguin, Yves ULg et al

in Heinz, Beverley C. (Ed.) Trends in Hodgkin's Disease Research (2005)

Hodgkin's disease, sometimes called Hodgkin's lymphoma, is a cancer that starts in lymphatic tissue. Lymphatic tissue includes the lymph nodes and related organs that are part of the body's immune and ... [more ▼]

Hodgkin's disease, sometimes called Hodgkin's lymphoma, is a cancer that starts in lymphatic tissue. Lymphatic tissue includes the lymph nodes and related organs that are part of the body's immune and blood-forming systems. The lymph nodes are small, bean-shaped organs found underneath the skin in the neck, underarm, and groin. They are also found in many other places in the body such as inside the chest, abdomen, and pelvis. Lymph nodes make and store infection-fighting white blood cells, called lymphocytes. They are connected throughout the body by lymph vessels (narrow tubes similar to blood vessels). These lymph vessels carry a colourless, watery fluid (lymphatic fluid) that contains lymphocytes. Eventually the lymphatic fluid is emptied into the blood vessels in the left upper chest. There are 5 different types of Hodgkin's lymphoma: Nodular sclerosing Hodgkin's lymphoma; Mixed cellularity Hodgkin's lymphoma; Lymphocyte depletion Hodgkin's lymphoma; Lymphocyte-rich classical Hodgkin's lymphoma; Nodular lymphocyte-predominant Hodgkin's lymphoma. This volume examines and presents leading-edge research in this field. Preface; What Causes Hodgkin’s Disease? A Review of Analytical Epidemiology; Progress in Hodgkin’s Disease Research; New Insights in Pediatric Hodgkin’s Disease; Hodgkin’s Lymphoma and Infection; Roles of CD30 Signal Transduction in the Biology of Classic Hodgkin’s Lymphoma; Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Staging and Response Assessment in Hodgkin’s Disease; The Clinical Value of Nuclear Medicine in the Assessment of Radio-and Chemotherapy Related Pulmonary and Cardiac Normal Tissue Damage in Patients with Hodgkin’s Disease; Cell Fusion and Carcinogenesis. Hodgkin and Reed-Sternberg Cells as Paradigm of Cell Fusion and Cell Cancerisation; Existential and Psychosocial Issues for Hodgkin’s Disease Survivors; Index. [less ▲]

Detailed reference viewed: 20 (2 ULg)
Full Text
Peer Reviewed
See detailLa 3'-deoxy-3'-[18F] fluorothymidine ([18F]-FLT) est-elle le prochain traceur utilise en routine pour la TEP apres le [18F]-FDG?
Couturier, Olivier; Leost, Francoise; Campone, Mario et al

in Bulletin du Cancer (2005), 92(9), 789-98

Positron emission tomography (PET) with [18F]-FDG is now firmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its ... [more ▼]

Positron emission tomography (PET) with [18F]-FDG is now firmly established as a clinical tool in oncology. Its applications are however limited in some indications, due to the lack of specificity of its uptake mechanism for tumors, or the low avidity of some cancer types such as prostate. Alternative tracers are thus being developed, in order to fill up this void. Proliferation as a biological target is particularly attractive in cancer imaging. From that perspective, fluorothymidine ([18F]-FLT or FLT) has generated a strong interest among the scientific community, especially since the radiosynthesis process has been improved and simplified, thus making possible to envision a routine use for the tracer. This article aims at summarizing the status of the current scientific data regarding FLT. The uptake mechanism of FLT is well known, relying on the thymidine kinase 1 (TK1) enzymatic activity, and thus on DNA synthesis. Preclinical studies have shown a clear relationship between tracer accumulation and level of tumor proliferation, even though DNA salvage pathwayss intervene in the process and may complicate the interpretation of the results. Several clinical studies suggest a good specificity for tumor, albeit with a lower sensitivity than with FDG. In all likelihood however, the future of FLT lies in the evaluation of antitumor response and possibly the pretherapeutic prognostic characterization, rather than in the diagnosis and staging of malignancies. Although the scientific data regarding this issue remain limited, initial results are encouraging. Further significant work remains to be done in order to fully assess the clinical performances of the tracer, on the one hand, and to determine its place relative to FDG and other emerging tracers, on the other hand. Until these studies are completed, FLT should be considered as a promising tracer, but remaining at an experimental stage of its development. [less ▲]

Detailed reference viewed: 70 (1 ULg)
Full Text
Peer Reviewed
See detailPET imaging in assessing gastrointestinal tumors
Hustinx, Roland ULg

in Radiologic Clinics of North America (2004), 42(6), 1123

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailFluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography
Couturier, Olivier; Chatal, Jean-François; Hustinx, Roland ULg

in Bulletin du Cancer (2004), 91(9), 695-703

F-18-FDG is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine 18 is considered as the ideal radioisotope for PET, thanks to a low positron energy ... [more ▼]

F-18-FDG is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine 18 is considered as the ideal radioisotope for PET, thanks to a low positron energy, which not only limits the dose rate to the patients but also provides high-resolution images. Furthermore, the 110 min. physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site, and imaging protocols that could span hours, which permits dynamic studies and assessing metabolic processes that may be fairly slow Recently, synthesis of fluorinated tracers from prosthetic group precursors, which allows easier radiolabeling of biomolecules, has given a boost to the development of numerous fluorinated tracers, Given the wide availability of fluorine 18, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated analogs of nucleosides and fluorinated radiotracers of gene expression recently developed and under investigation. [less ▲]

Detailed reference viewed: 27 (3 ULg)
Full Text
Peer Reviewed
See detailFluorinated tracers for imaging cancer with positron emission tomography
Couturier, Olivier; Luxen, André ULg; Chatal, Jean-François et al

in European Journal of Nuclear Medicine and Molecular Imaging (2004), 31(8), 1182-1206

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET ... [more ▼]

2-[F-18]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism. [less ▲]

Detailed reference viewed: 37 (2 ULg)
Full Text
Peer Reviewed
See detailAssessment of disease activity in rheumatoid arthritis with 18F-FDG PET
Beckers, Catherine ULg; Ribbens, Clio ULg; Andre, Béatrice ULg et al

in Journal of Nuclear Medicine (2004), 45(6), 956-964

The aim of this study was to assess synovitis by F-18-FDG PET in an individual joint analysis and in a global analysis of rheumatoid arthritis (RA) disease activity and to compare F-18-FDG PET parameters ... [more ▼]

The aim of this study was to assess synovitis by F-18-FDG PET in an individual joint analysis and in a global analysis of rheumatoid arthritis (RA) disease activity and to compare F-18-FDG PET parameters with clinical, biologic, and sonographic (US) rheumatoid parameters. Methods: Three hundred fifty-six joints were assessed in 21 patients with active RA: the knees in all subjects and either wrists as well as metacarpophalangeal and proximal interphalangeal joints in 13 patients, or ankles and the first metatarsophalangeal joints in the remaining 8 patients. PET analysis consisted of a visual identification of F-18-FDG uptake in the synovium and measurements of standardized uptake values (SUVs). Independent assessors performed the clinical and US examinations. Results: PET positivity was found in 63% of joints, whereas 75%, 79%, and 56% were positive for swelling, tenderness, and US analysis, respectively. Both the rate of PET-positive joints and the SUV increased with the number of positive parameters present (swelling, tenderness, US positivity) and with the synovial thickness. The mean SUV was significantly higher in joints where a power Doppler signal was found. In a global PET analysis, the number of PET-positive joints and the cumulative SUV were significantly correlated with the swollen and tender joint counts, the patient and physician global assessments, the erythrocyte sedimentation rate and C-reactive protein serum levels, the disease activity score and the simplified disease activity index, the number of US-positive joints, and the cumulative synovial thickness. Conclusion: F-18-FDG PET is a unique imaging technique that can assess the metabolic activity of synovitis and measure the disease activity in RA. [less ▲]

Detailed reference viewed: 116 (7 ULg)
Full Text
Peer Reviewed
See detailContribution of Pet Scanning to the Evaluation of Abdominal Aortic Aneurysm
Sakalihasan, Natzi ULg; Hustinx, Roland ULg; Limet, Raymond ULg

in Seminars in Vascular Surgery (2004), 17(2), 144-53

The size of abdominal aortic aneurysms (AAA) is the most usual predictor of the risk for rupture. Because chronic metalloproteinases production and activation by inflammatory cells causes degradation of ... [more ▼]

The size of abdominal aortic aneurysms (AAA) is the most usual predictor of the risk for rupture. Because chronic metalloproteinases production and activation by inflammatory cells causes degradation of elastin and collagen in the aneurysmal wall, the detection of an increased metabolic process preceding fissuration and rupture could be a more sensitive predictor of rupture risk. We investigated the metabolic activity of the aneurysmal wall by whole-body positron emission tomography (PET) in 26 patients with a documented AAA (mean diameter 63 mm, extremes 45 mm and 78 mm). A positive (18)F-fluorodeoxyglucose ((18)F-FDG) uptake at the level of the AAA was observed in 38% of the cases (10 of 26 patients). Nine of these 10 patients required emergent or urgent aneurysmectomy for ruptured (n = 1), leaking (n = 1), rapidly expanding (n = 2), or painful (n = 5) aneurysms; the negative (18)F-FDG uptake patients had a more benign course. This preliminary study suggests a possible correlation between (18)F-FDG uptake by the aneurysm wall and the triggering of processes leading to rupture. The (18)F-FDG uptake in the aneurysm wall may correspond to the accumulation of inflammatory cells responsible for the production and activation of degrading enzymes. PET scan seems useful in high-risk patients. Positive PET imaging in these cases would help us to decide to proceed with surgery, despite factors favoring a surveillance strategy. [less ▲]

Detailed reference viewed: 64 (8 ULg)
Full Text
Peer Reviewed
See detailWithin-patient variability of F-18-FDG: Standardized uptake values in normal tissues
Paquet, Nancy; Albert, Adelin ULg; Willems, Jacqueline ULg et al

in Journal of Nuclear Medicine (2004), 45(5), 784-788

The aim of this study was to evaluate the test-retest variability of standardized uptake values (SUVs) in normal tissues and the impact of various methods for measuring the SUV. Methods: SUVs were ... [more ▼]

The aim of this study was to evaluate the test-retest variability of standardized uptake values (SUVs) in normal tissues and the impact of various methods for measuring the SUV. Methods: SUVs were determined in 70 cancer-free patients (40 female and 30 male) on 2 occasions an average of 271 d apart. Mean values for body weight and height, blood glucose level, injected dose, and uptake period did not change between the 2 groups of studies. Four regions of interest (ROIs) were placed-on the liver, lung, mediastinum, and trapezius muscle. Mean and maximum SUVs normalized for body weight were obtained, and normalizations were then applied for lean body mass (LBM), LBM and blood glucose level, body surface area (BSA), and BSA and blood glucose level. Results: In the lungs and muscle, metabolic activity within the ROIs was significantly different in the 2 studies, no matter which method was used for the SUVs. The differences ranged from 0.02 to 0.1 for SUV normalized for body weight and SUV normalized for LBM and from 0.001 to 0.002 for SUV normalized for BSA. In the liver, results were similar for all SUVs, except for maximum SUV corrected for LBM and maximum SUV corrected for LBM and blood glucose level. The metabolic activity measured in the mediastinum was also comparable in the 2 studies, regardless of the type of SUV. When investigating whether any normalization method for SUVs reduces variability and improves test-retest concordance, we found no significant superiority for any. The best intraclass correlation coefficients were obtained with the SUV normalized for body weight, in both the liver and the mediastinum, but the coefficients of variation were similar for all 3 mean SUVs that were not corrected for glucose level (range, 10.8%-13.4%). However, normalizing for blood glucose level increased the variability and decreased the level of concordance between studies. Conclusion: The SUVs measured in normal liver and mediastinum in cancer-free patients are stable over time, no matter which normalization is used. Correcting for blood glucose level increases the variability of the values and should therefore be avoided. Normalizing for BSA or LBM does not improve the reproducibility of the measurements. [less ▲]

Detailed reference viewed: 30 (5 ULg)
Full Text
Peer Reviewed
See detail18F-tyrosine PET in Neurooncology : an alternative to 11C-methionine.
KASCHTEN; LEMAIRE, C.; LUXEN, A. et al

in Journal of Nuclear Medicine (The) (2004), 45(SUPPL), 264

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailTraceurs fluorés de la prolifération des cancers en tomographie par émission de positons
Couturier, Olivier; Bodet-Milin, C.; Cherel, M. et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2004), 28(8), 371-376

Le 18F-fluorodeoxyglucose (FDG) est actuellement le seul traceur fluoré utilisé en routine en tomographie par émission de positons (TEP). Le fluor 18 peut être considéré comme le radioisotope TEP idéal ... [more ▼]

Le 18F-fluorodeoxyglucose (FDG) est actuellement le seul traceur fluoré utilisé en routine en tomographie par émission de positons (TEP). Le fluor 18 peut être considéré comme le radioisotope TEP idéal avec : 1) une émission positonique de faible énergie (0,64 MeV), limitant l'irradiation reçue par le patient ainsi que le parcours du positon dans les tissus (2,3 mm), avec comme conséquence directe, une haute résolution des images TEP; 2) une période de 110 minutes permettant une radiosynthèse avec un bon rendement, un transport depuis l'établissement de radiopharmacie vers des services de médecine nucléaire distants, et des protocoles d'imagerie pouvant s'étendre sur quelques heures, ce qui facilite les études dynamiques et de processus métaboliques relativement lents. Récemment, la radiosynthèse fluorée à partir de groupes prothétiques précurseurs, qui permet le marquage de molécules bioactives dans de bonnes conditions, a donné un nouvel élan au développement de nombreux traceurs fluorés. En raison de la disponibilité du fluor, ils pourraient occuper dans un avenir proche une place importante en routine. Cet article et une revue de la littérature concernant les traceurs fluorés récemment développés et/ou en cours d'investigation, susceptibles d'être employés pour évaluer la prolifération tumorale. [less ▲]

Detailed reference viewed: 48 (8 ULg)
Full Text
See detailNew strategies and new impact of cancer imaging
Couturier, Olivier; Hustinx, Roland ULg; Chatal, Jean-François

in SERVIER, Jacques (Ed.) Cancer : recent evidence, innovative strategies, future promises (2004)

Detailed reference viewed: 15 (0 ULg)
Full Text
See detailPET in lung cancer
Rigo, Pierre ULg; Hustinx, Roland ULg; Bury, Thierry ULg

in Bailey, D. L.; Townsend, D. W.; Valk, P. E. (Eds.) et al Positron emission tomography. Principles and practice (2004)

Positron Emission Tomography - basic science and clinical practice thoroughly explains the principles, clinical applications and economic aspects of PET today. Chapters go into detail on PET applications ... [more ▼]

Positron Emission Tomography - basic science and clinical practice thoroughly explains the principles, clinical applications and economic aspects of PET today. Chapters go into detail on PET applications in oncology, the central nervous system, cardio-respiratory systems, infectious diseases and pediatrics. Discussions are also found on technology design and evaluation, PET in drug discovery and development, and in imaging gene expression and therapy. [less ▲]

Detailed reference viewed: 31 (2 ULg)
Full Text
Peer Reviewed
See detailTomographie a emission de positons: une revolution en cancerologie?
Jerusalem, Guy ULg; Hustinx, Roland ULg

in Revue du Praticien (La) (2003), 53(15), 1629-30

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailWhole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome)
Alberini, J. L.; Belhocine, Tarik; Hustinx, Roland ULg et al

in Nuclear Medicine Communications (2003), 24(10), 1081-1086

The aim of this study was to evaluate the clinical performances of whole body 2-[F-18]fluorodeoxyglucose positron emission tomography (FDG PET) imaging for the detection of the primary tumour in patients ... [more ▼]

The aim of this study was to evaluate the clinical performances of whole body 2-[F-18]fluorodeoxyglucose positron emission tomography (FDG PET) imaging for the detection of the primary tumour in patients with metastases of unknown origin. Forty-one patients, without previous history of known cancer (18 women and 23 men; average age 64.1 years) with metastasis confirmed by histopathological analysis were included in a retrospective study. Results of PET were compared with those of techniques used in the current conventional diagnostic procedure. All known metastatic lesions were detected by PET. There were 26 true-positive and two false-negative results. Primary tumour remained undetermined in eight patients after conventional investigations and PET. PET was superior to conventional diagnostic procedure in 11 patients and led to modify treatment in 11 patients. Sensitivity of PET was superior than computed tomography in detecting abdominal primary tumours. FDG PET is useful in patients with unknown primary tumour because its sensitivity is good and it could modify the disease management. Otherwise, PET allows the evaluation of the extent of the disease and could be used to monitor treatment efficiency. Its contribution has to be evaluated particularly in patients with primary tumour with a specific treatment. ((C) 2003 Lippincott Williams Wilkins). [less ▲]

Detailed reference viewed: 27 (3 ULg)
Full Text
Peer Reviewed
See detailImaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data
Belhocine, Tarik; Blockmans, Daniel; Hustinx, Roland ULg et al

in European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(9), 1305-1313

Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients ... [more ▼]

Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients suffering from non-malignant diseases such as inflammatory or infectious diseases may also derive clinical benefit from the appropriate use of metabolic imaging. Large vessel vasculitides such as giant cell arteritis and Takayasu arteritis are other examples that may potentially extend the field of (18)FDG PET indications. The purpose of the present article is to assess the feasibility of metabolic imaging in vasculitis on the basis of the current literature data. In particular, the clinical context and the (18)FDG imaging patterns seen in patients with large vessel vasculitis are analysed in order to identify potential indications for metabolic imaging. [less ▲]

Detailed reference viewed: 46 (1 ULg)